Evidence map›Paper›PMID 28779221›Full record

ArticleClinical oral investigations2018

Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential.

Božana Lončar-Brzak, Marko Klobučar, Irena Veliki-Dalić, Ivan Sabol, Sandra Kraljević Pavelić, Božo Krušlin, Marinka Mravak-Stipetić

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical oral investigations, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Salivary biglycan-neo-epitope-BGNOsteoarthritis and cartilage open · 2023
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Božana Lončar-BrzakSchool of Dental Medicine, Department of Oral Medicine, University of Zagreb, Zagreb, Croatia.
Marko KlobučarDepartment of Biotechnology and Centre for High-throughput technologies, University of Rijeka, Radmile Matejčić 2, 51000, Rijeka, Croatia.
Irena Veliki-DalićDepartment of Pathology, Clinical Hospital for Tumours, Clinical Hospital Centre Sisters of Mercy, Zagreb, Croatia.
Ivan SabolDivision of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Sandra Kraljević PavelićDepartment of Biotechnology and Centre for High-throughput technologies, University of Rijeka, Radmile Matejčić 2, 51000, Rijeka, Croatia. sandrakp@biotech.uniri.hr.ORCID http://orcid.org/0000-0003-0491-673X
Božo KrušlinSchool of Medicine, Department of Pathology, Clinical Hospital Centre Sisters of Mercy, University of Zagreb, Zagreb, Croatia.
Marinka Mravak-StipetićSchool of Dental Medicine, Department of Oral Medicine, University of Zagreb, Zagreb, Croatia.
University Hospital Centre Zagreb · HRUniversity of Rijeka · HRUniversity of Zagreb · HRRuđer Bošković Institute · HR

Funding

European Regional Development Fund (ERDF). Research Infrastructure for Campus-based Laboratories at University of RijekaMinistry of Science, Education and Sports of the Republic of Croatia 065-0982464-2532University of Rijeka research grant 13.11.1.1.11
6 · The paper itself

Abstract

objectivesThe aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (OLP), oral squamous cell carcinoma (OSCC) and healthy mucosa. MATERIALS AND

methodsGlobal protein profiling methods based on liquid chromatography coupled to mass spectrometry (LC-MS) were used, with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, as well as on analyses of IG2F and IGFR2 expression in healthy mucosa, OLP and OSCC tissues by comparative semi-quantitative immunohistochemistry.

resultsMass spectrometry-based proteomics profiling of healthy mucosa, OLP and OSCC tissues (and accompanied histologically unaltered tissues, respectively) identified 55 extracellular matrix proteins. Twenty among identified proteins were common to all groups of samples. Expression of small leucine-rich extracellular matrix proteoglycans lumican and biglycan was found both in OSCC and OLP and they were validated by Western blot analysis as putative biomarkers. A significant increase (p < 0.05) of biglycan expression in OLP-AT group was determined in comparison with OLP-T group, while lumican showed significant up-regulation (p < 0.05) in OLP-T and OSCC-T groups vs. adjacent and control tissue groups. Biglycan expression was only determined in OSCC-AT group. Immunohistochemical analysis of IGF2 and IG2FR expression revealed no significant difference among groups of samples. CONCLUSION/CLINICAL RELEVANCE: Biglycan and lumican were identified as important pathogenesis biomarkers of OLP that point to its malignant potential.

Indexed as

BiglycanBiomarkers, TumorBiopsyBlotting, WesternCarcinoma, Squamous CellChromatography, LiquidExtracellular Matrix ProteinsFemaleHumansImmunohistochemistryLichen Planus, OralLumicanMaleMass SpectrometryMiddle AgedMouth NeoplasmsBiglycanBiomarkers, TumorExtracellular Matrix ProteinsLumicanBiglycanIGF2IGF2RLumicanOral lichen planusProteomics

Identifiers

PMID28779221
OpenAlexW2744340068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.